AstraZeneca shares seen slipping 3% after reported Bristol Myers talks

Aug. 3 (Reuters) - AstraZeneca AZN.L shares are expected to drop up to 3% on Monday, according to traders, after reports that the European pharmaceutical giant held preliminary talks about a possible combination with U.S.-based Bristol Myers Squibb BMY.N.

(Reporting by Prerna Bedi and Pushkala Aripaka in Bengaluru; Editing by Nivedita Bhattacharjee)